MX2008000141A - Moduladores de lxr basados en imidazol. - Google Patents

Moduladores de lxr basados en imidazol.

Info

Publication number
MX2008000141A
MX2008000141A MX2008000141A MX2008000141A MX2008000141A MX 2008000141 A MX2008000141 A MX 2008000141A MX 2008000141 A MX2008000141 A MX 2008000141A MX 2008000141 A MX2008000141 A MX 2008000141A MX 2008000141 A MX2008000141 A MX 2008000141A
Authority
MX
Mexico
Prior art keywords
sup
compounds
lxr modulators
imidazole based
based lxr
Prior art date
Application number
MX2008000141A
Other languages
English (en)
Inventor
Brenton T Flatt
Raju Mohan
Michael Charles Nyman
William C Stevens Jr
Brett B Busch
Xiao-Hui Gu
Shao-Po Lu
Richard Martin
Edwin Schweiger
Tie-Lin Wang
Yinong Xie
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37309323&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2008000141(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MX2008000141A publication Critical patent/MX2008000141A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Abstract

(Ver formulas) Compuestos de la invencion, tales como compuestos de las formulas IIa, IIb, IIc, o IId, y sales farmaceuticamente aceptables, isomeros o profarmacos de ellos, son utiles como inhibidores de la actividad de los receptores X del higado, en donde R1, R2, R11, R3 y G se definen en la presente. Tambien se revelan composiciones farmaceuticas que contienen los receptores y metodos de uso de los compuestos.
MX2008000141A 2005-06-27 2006-06-26 Moduladores de lxr basados en imidazol. MX2008000141A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69437205P 2005-06-27 2005-06-27
US73612005P 2005-11-10 2005-11-10
PCT/US2006/024757 WO2007002563A1 (en) 2005-06-27 2006-06-26 Imidazole based lxr modulators

Publications (1)

Publication Number Publication Date
MX2008000141A true MX2008000141A (es) 2008-04-07

Family

ID=37309323

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008000141A MX2008000141A (es) 2005-06-27 2006-06-26 Moduladores de lxr basados en imidazol.

Country Status (18)

Country Link
US (3) US8703805B2 (es)
EP (2) EP1910307A1 (es)
JP (2) JP5244589B2 (es)
KR (2) KR101363278B1 (es)
AR (2) AR054521A1 (es)
AU (2) AU2006261845C1 (es)
BR (1) BRPI0612287A8 (es)
CA (2) CA2613522A1 (es)
ES (1) ES2525217T3 (es)
IL (1) IL188239A0 (es)
MX (1) MX2008000141A (es)
MY (1) MY152162A (es)
NO (1) NO20080391L (es)
NZ (1) NZ564916A (es)
PE (2) PE20070105A1 (es)
SG (1) SG162804A1 (es)
TW (2) TW200745045A (es)
WO (2) WO2007002559A1 (es)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004000260T2 (de) 2003-07-22 2006-08-24 Arena Pharmaceuticals, Inc., San Diego Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
PE20061130A1 (es) 2004-11-19 2007-01-05 Arena Pharm Inc Derivados de 3-fenil-pirazol como moduladores del receptor de serotonina 5-ht2a
CA2613522A1 (en) 2005-06-27 2007-01-04 Exelixis, Inc. Imidazole based lxr modulators
AU2013200480B2 (en) * 2006-02-28 2016-06-09 Dart Neuroscience (Cayman) Ltd. Therapeutic compounds
ES2462240T3 (es) 2006-02-28 2014-05-22 Dart Neuroscience (Cayman) Ltd Piperazinas terapéuticas como inhibidores de PDE4
AU2007221020B9 (en) * 2006-02-28 2013-04-04 Dart Neuroscience (Cayman) Ltd. Therapeutic compounds
EP3395816A1 (en) 2006-05-18 2018-10-31 Arena Pharmaceuticals, Inc. Ethers, secondary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
CA2646081C (en) 2006-05-18 2017-06-27 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor
ES2536762T3 (es) 2006-05-18 2015-05-28 Arena Pharmaceuticals, Inc. Aminas primarias y sus derivados como moduladores del receptor de la serotonina 5-HT2A útiles para el tratamiento de trastornos relacionados con este
ES2444695T3 (es) 2006-06-23 2014-02-26 Alethia Biotherapeutics Inc. Polinucleótidos y polipéptidos implicados en el cáncer
TWI408136B (zh) * 2006-10-02 2013-09-11 Nat Health Research Institutes 噻吩化合物及其醫藥組成物
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
US8193225B2 (en) * 2006-10-13 2012-06-05 The Board Of Regents Of The University Of Texas System Isoxazole amides, derivatives and methods of chemical induction of neurogenesis
CN101679297B (zh) * 2006-12-08 2012-01-11 埃克塞利希斯股份有限公司 Lxr和fxr调节剂
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
CN103087043A (zh) * 2007-03-16 2013-05-08 中国人民解放军军事医学科学院放射与辐射医学研究所 具有抗增殖活性的苯甲酰胺类衍生物及其药用制剂
CA2687306A1 (en) * 2007-05-18 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
CN101687790B (zh) * 2007-05-25 2015-02-11 Abbvie公司 作为代谢型谷氨酸受体2(mglu2受体)的正向调节剂的杂环化合物
US20100197767A1 (en) * 2007-07-11 2010-08-05 Lior Nissim Nucleic acid construct systems capable of daignosing or treating a cell state
CA2695517C (en) 2007-08-03 2016-09-20 J. Edward Semple Alkylsulfonyl-substituted thiazolide compounds
WO2009023253A2 (en) 2007-08-15 2009-02-19 Arena Pharmaceuticals Inc. IMIDAZO[L,2-α]PYRIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO
WO2009029632A1 (en) 2007-08-27 2009-03-05 Helicon Therapeutics, Inc. Therapeutic isoxazole compounds
CA2698332C (en) * 2007-09-06 2012-08-21 Merck Sharp & Dohme Corp. Pyrazole derivatives as soluble guanylate cyclase activators
US9029411B2 (en) 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
DE102008015033A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte (Pyrazolyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008015032A1 (de) 2008-03-17 2009-09-24 Aicuris Gmbh & Co. Kg Substituierte Pyrazolamide und ihre Verwendung
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
US8063088B2 (en) * 2008-06-11 2011-11-22 Hoffmann-La Roche Inc. Imidazolidine derivatives
ES2666324T3 (es) 2008-10-28 2018-05-04 Arena Pharmaceuticals, Inc. Composiciones de un modulador del receptor de serotonina 5-HT2A útiles para el tratamiento de trastornos relacionados con el mismo
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
CN104829714A (zh) 2008-11-03 2015-08-12 阿莱斯亚生物疗法股份有限公司 特异性地阻滞肿瘤抗原的生物活性的抗体
DE102009041241A1 (de) 2009-09-11 2011-08-04 Bayer Schering Pharma Aktiengesellschaft, 13353 Substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057343A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057344A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057364A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041242A1 (de) 2009-09-11 2011-12-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
DE102008062863A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte (Thiophenyl-carbonyl)imidazolidinone und ihre Verwendung
DE102008062878A1 (de) 2008-12-17 2010-06-24 Aicuris Gmbh & Co. Kg Substituierte Furancarboxamide und ihre Verwendung
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CN102395585A (zh) 2009-01-30 2012-03-28 米伦纽姆医药公司 杂芳基化合物和其作为pi3k抑制剂的用途
SG172926A1 (en) 2009-01-30 2011-08-29 Glaxosmithkline Llc Crystalline n-{(1-s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
CN102414194A (zh) * 2009-02-26 2012-04-11 默沙东公司 可溶性鸟苷酸环化酶激活剂
DK2607348T3 (da) 2009-03-31 2021-05-25 Renascience Inc Inhibitor af plasminogenaktivatorinhibitor-1
CN105853415A (zh) 2009-05-12 2016-08-17 罗马克实验室有限公司 卤代烷基杂芳基苯甲酰胺化合物
ES2620451T3 (es) * 2009-05-28 2017-06-28 Exelixis Patent Company Llc Moduladores de los LXR
JP5932640B2 (ja) 2009-06-26 2016-06-08 ロマーク ラボラトリーズ エル．シー． インフルエンザを治療するための化合物および方法
DE102009036604A1 (de) 2009-07-30 2011-02-03 Aicuris Gmbh & Co. Kg Substituierte Bis-Arylpyrazolamide mit terminaler primärer Amidfunktionalisierung und ihre Verwendung
JP2011057661A (ja) * 2009-08-14 2011-03-24 Bayer Cropscience Ag 殺虫性カルボキサミド類
US8980891B2 (en) 2009-12-18 2015-03-17 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
JP2013525448A (ja) * 2010-04-27 2013-06-20 カルシメディカ，インク． 細胞内カルシウムを調節する化合物
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2395003A1 (en) * 2010-05-27 2011-12-14 Laboratorios Del. Dr. Esteve, S.A. Pyrazole compounds as sigma receptor inhibitors
US9365574B2 (en) 2010-05-27 2016-06-14 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
WO2012003405A1 (en) 2010-06-30 2012-01-05 Ironwood Pharmaceuticals, Inc. Sgc stimulators
KR101891838B1 (ko) 2010-07-15 2018-09-28 다이닛본 스미토모 세이야꾸 가부시끼가이샤 피라졸 화합물
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
PE20131304A1 (es) 2010-08-11 2013-11-14 Millennium Pharm Inc Heteroarilos y sus usos
JP2013533318A (ja) 2010-08-11 2013-08-22 ミレニアム ファーマシューティカルズ， インコーポレイテッド ヘテロアリールおよびその使用
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
CA2811145A1 (en) 2010-09-07 2012-03-15 Snu R&Db Foundation Sesterterpene compound and use thereof
UY33671A (es) 2010-10-13 2012-04-30 Millenium Pharmaceuticals Inc Heteroarilos y sus usos
NZ609955A (en) 2010-11-09 2015-05-29 Ironwood Pharmaceuticals Inc Sgc stimulators
ES2624131T3 (es) * 2011-03-08 2017-07-13 3-V Biosciences, Inc. Moduladores heterocíclicos de la síntesis de lípidos
AR088728A1 (es) * 2011-03-25 2014-07-02 Bristol Myers Squibb Co Moduladores de lxr como prodroga de imidazol
DK3173427T3 (da) 2011-03-31 2019-08-05 Adc Therapeutics Sa Antistoffer mod nyre-associeret antigen 1 og antigen-bindende fragmenter deraf
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
PE20140868A1 (es) 2011-06-24 2014-07-18 Amgen Inc Antagonistas trpm8 y su uso en tratamientos
EP2723718A1 (en) 2011-06-24 2014-04-30 Amgen Inc. Trpm8 antagonists and their use in treatments
DE102011055815A1 (de) 2011-11-29 2013-05-29 Aicuris Gmbh & Co. Kg Carboxamid-substituierte Heteroaryl-Pyrazole und ihre Verwendung
EP2797915B1 (en) 2011-12-27 2016-07-13 Ironwood Pharmaceuticals, Inc. 2-benzyl-3-(oxazole/thiazole)-5-(pyrimidin-2-yl)-1(H)-pyrazole derivatives as stimulators of the soluble guanylate cyclase (sGC) for the treatment of e.g. hypertension or heart failure
ES2731665T3 (es) 2012-01-09 2019-11-18 Adc Therapeutics Sa Agentes para tratar cáncer de mama triple negativo
HUE040231T2 (hu) 2012-03-02 2019-02-28 Ralexar Therapeutics Inc Máj X receptor (LXR) modulátorok bõrbetegségek, rendellenességek és állapotok kezelésére
WO2013138753A1 (en) 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Prodrugs of riluzole and their method of use
US8859781B2 (en) * 2012-07-12 2014-10-14 Euclises Pharmaceuticals, Inc. No-releasing nonoate(nitrogen-bound)sulfonamide-linked-coxib anti-cancer agents
EP2877464B1 (en) * 2012-07-24 2016-08-24 Boehringer Ingelheim International GmbH N-cyclopropyl-n-piperidinyl-amide derivatives and their use as gpr119 modulators
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
JP6320382B2 (ja) * 2012-08-13 2018-05-09 ザ ロックフェラー ユニヴァーシティ メラノーマの処置および診断
DE102012016908A1 (de) 2012-08-17 2014-02-20 Aicuris Gmbh & Co. Kg Tris-(Hetero)Aryl-Pyrazole und ihre Verwendung
EP2892888B1 (en) * 2012-09-10 2018-04-18 Boehringer Ingelheim International GmbH N-cyclopropyl-n-piperidinyl-amides, pharmaceutical compositions containing them, and uses thereof
CN102924347A (zh) * 2012-11-21 2013-02-13 徐州宇家化工科技有限公司 苯基甲基砜衍生物的制备方法
CN104884058A (zh) 2013-01-10 2015-09-02 格吕伦塔尔有限公司 作为crac通道抑制剂的基于吡唑基的甲酰胺ii
JP2016508152A (ja) 2013-01-10 2016-03-17 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｃｒａｃチャネル阻害薬としての、ピラゾリルをベースとするカルボキサミド類ｉ
EP2961746B1 (en) 2013-02-28 2018-01-03 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
TW201444798A (zh) 2013-02-28 2014-12-01 必治妥美雅史谷比公司 作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物
US9834542B2 (en) 2013-03-15 2017-12-05 Bristo-Myers Squibb Company LXR modulators
US10000459B2 (en) 2013-03-15 2018-06-19 Epigen Biosciences, Inc. Heterocyclic compounds useful in the treatment of disease
JP6456909B2 (ja) * 2013-03-15 2019-01-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｌｘｒ調節因子
WO2014171464A1 (ja) 2013-04-15 2014-10-23 株式会社レナサイエンス Ｐａｉ－１阻害剤の新規用途
WO2014199164A1 (en) * 2013-06-12 2014-12-18 Ampla Pharmaceuticals, Inc. Diaryl substituted heteroaromatic compounds
ES2804304T3 (es) * 2013-09-04 2021-02-05 Ellora Therapeutics Inc Moduladores del receptor X hepático (LXR)
CA2923178A1 (en) * 2013-09-04 2015-03-12 Alexar Therapeutics, Inc. Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions
CN103588758A (zh) * 2013-11-04 2014-02-19 南京大学 一类含1,4-苯并二噁烷骨架的硝基咪唑衍生物的合成、制备及其在抗癌药物中的应用
US9231217B2 (en) 2013-11-28 2016-01-05 Semiconductor Energy Laboratory Co., Ltd. Synthesis method of organometallic complex, synthesis method of pyrazine derivative, 5,6-diaryl-2-pyrazyl triflate, light-emitting element, light-emitting device, electronic device, and lighting device
EP3082782A1 (en) 2013-12-17 2016-10-26 Laboratorios Del. Dr. Esteve, S.A. SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS
WO2015103060A1 (en) 2014-01-06 2015-07-09 Algomedix, Inc. Trpa1 modulators
AU2015204572B2 (en) 2014-01-10 2020-07-30 Inspirna, Inc. LXR agonists and uses thereof
AR101816A1 (es) 2014-04-02 2017-01-18 Bayer Cropscience Ag Derivados de 3-[(pirazol-5-il)-heteroaril]-benzamidas como agentes pesticidas
US9969726B2 (en) * 2014-06-10 2018-05-15 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (NAMS) and uses thereof
WO2015197187A1 (en) 2014-06-24 2015-12-30 Grünenthal GmbH Pyrazolyl-based carboxamides v
CN107108581B (zh) 2014-08-21 2020-06-23 百时美施贵宝公司 作为强效rock抑制剂的回接苯甲酰胺衍生物
JP2018516992A (ja) 2015-06-12 2018-06-28 アクソファント サイエンシーズ ゲーエムベーハーＡｘｏｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ レム睡眠行動障害の予防および処置のために有用なジアリールおよびアリールヘテロアリール尿素誘導体
RU2018103338A (ru) 2015-07-15 2019-08-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины для профилактики и лечения галлюцинаций, ассоциированных с нейродегенеративным заболеванием
PT3395801T (pt) * 2015-12-16 2021-05-24 Nippon Soda Co Composto de arilazol e agente de controlo de pragas
EP3402477A4 (en) 2016-01-11 2019-08-21 The Rockefeller University METHODS FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH SUPPRESSIVE CELLS DERIVED FROM MYELOID CELLS
US10702506B2 (en) 2016-02-26 2020-07-07 The Regents Of The University Of California Small molecule inhibitors of pendrin ion exchange and pharmaceutical compositions
CA3032229A1 (en) 2016-07-27 2018-02-01 Hartis-Pharma Sa Therapeutic combinations to treat red blood cell disorders
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
WO2019036024A1 (en) 2017-08-17 2019-02-21 Bristol-Myers Squibb Company 2- (1,1'-BIPHENYL) -1H-BENZO [D] IMIDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS AGONISTS OF APELIN AND APJ FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
WO2019104062A1 (en) 2017-11-21 2019-05-31 Rgenix, Inc. Polymorphs and uses thereof
MX2020007956A (es) 2018-01-29 2021-01-08 Capulus Therapeutics Llc Inhibidores de la proteína de unión al elemento regulador de esterol (srebp) que comprenden un anillo central de 6 miembros.
WO2019165158A1 (en) * 2018-02-22 2019-08-29 University Of Florida Research Foundation, Incorporated Il-6 inhibitors and methods of treatment
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US11174220B2 (en) 2019-12-13 2021-11-16 Inspirna, Inc. Metal salts and uses thereof
WO2021120890A1 (en) * 2019-12-20 2021-06-24 Novartis Ag Pyrazolyl derivatives useful as anti-cancer agents
CA3166630A1 (en) 2020-01-03 2021-07-08 Berg Llc Polycyclic amides as ube2k modulators for treating cancer
CA3170055A1 (en) * 2020-03-02 2021-09-10 Trustees Of Tufts College Imidazole-based synthetic lipidoids for in vivo mrna delivery into immune cells
WO2023004280A1 (en) * 2021-07-19 2023-01-26 The Board Of Trustees Of The Leland Stanford Junior University Selective pyrazole lrrk2 inhibitors and methods for use thereof

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US655563A (en) * 1900-03-03 1900-08-07 Hewitt Lindstrom Motor Company Electric carriage.
GB1510107A (en) 1974-05-23 1978-05-10 Sandoz Products Ltd Benzimidazolyl-furan derivatives and use thereof as optical brighteners
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
JPS5726653A (en) * 1980-05-09 1982-02-12 Ciba Geigy Ag Substituted phenyl ether
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
AU570021B2 (en) 1982-11-22 1988-03-03 Novartis Ag Analogs of mevalolactone
US4559394A (en) 1983-06-03 1985-12-17 Phillips Petroleum Company Olefin polymerization using activated chromium catalyst treated with tertiary alcohol
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
IL82856A0 (en) 1986-06-26 1987-12-20 Norwich Eaton Pharma Pharmaceutical compositions containing 2-(5-phenyl-2-furanyl)imidazoles and certain such novel compounds
US4895867A (en) 1986-06-26 1990-01-23 Norwich Eaton Pharmaceuticals, Inc. 2-(5-phenyl-2-furanyl)imidazoles useful as cardiotonic agents
US5221623A (en) 1986-07-22 1993-06-22 Boyce Thompson Institute For Plant Research, Inc. Use of bacterial luciferase structural genes for cloning and monitoring gene expression in microorganisms and for tagging and identification of genetically engineered organisms
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US5070012A (en) 1988-03-30 1991-12-03 The Board Of Trustees Of The Leland Stanford Junior University Monitoring of cells and trans-activating transcription elements
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
US5283179A (en) 1990-09-10 1994-02-01 Promega Corporation Luciferase assay method
DE69232537T2 (de) 1991-09-17 2002-10-24 Salk Inst For Biolog Studies L Rezeptoren der steroid/thyroid superfamilie von rezeptoren
US6492411B1 (en) 1993-11-30 2002-12-10 G. D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
CA2276945C (en) * 1993-11-30 2006-08-01 G.D. Searle & Co. Tricyclic-substituted pyrazolyl benzenesulfonamides and pharmaceutical compositions thereof
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
EP0743520A3 (en) 1993-12-30 1999-11-10 The Salk Institute For Biological Studies Novel uses for GAL4-receptor constructs
JP3466765B2 (ja) 1994-07-27 2003-11-17 キッコーマン株式会社 ビオチン化ホタルルシフェラーゼ、ビオチン化ホタルルシフェラーゼ遺伝子、新規な組み換え体ｄｎａ、ビオチン化ホタルルシフェラーゼの製造法及び生物発光分析法
WO1996014302A1 (en) * 1994-11-08 1996-05-17 Eisai Co., Ltd. Pyrazole derivatives exhibiting anti-inflammatory and analgesic effects
US6005086A (en) 1995-01-13 1999-12-21 The Salk Institute For Biological Studies Farnesoid activated receptor polypeptides, and nucleic acid encoding the same
US5747661A (en) 1995-01-13 1998-05-05 Howard Hughes Medical Institute Retinoid-inducible response elements
US5741657A (en) 1995-03-20 1998-04-21 The Regents Of The University Of California Fluorogenic substrates for β-lactamase and methods of use
JP3964478B2 (ja) * 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
US5955604A (en) 1996-10-15 1999-09-21 The Regents Of The University Of California Substrates for β-lactamase and uses thereof
ES2179254T3 (es) * 1996-11-04 2003-01-16 Bayer Cropscience Sa 1-poliarilpirazoles plaguicidas.
JP2001509165A (ja) 1997-01-24 2001-07-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア バリヤ機能の回復、表皮の分化の促進及び増殖の抑制のためのＦＸＲ、ＰＰＡＲα及びＬＸＲαの活性剤の使用
US20020035156A1 (en) * 1997-04-18 2002-03-21 Barbara Roniker Combination therapy in the prevention of cardiovascular disorders
AU4229999A (en) * 1998-06-05 1999-12-20 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents
US6294558B1 (en) * 1999-05-31 2001-09-25 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
EP1115853A2 (en) 1998-09-23 2001-07-18 Ludmila Solomin Analysis of ligand activated nuclear receptors in vivo
GB9824310D0 (en) * 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
DE69940958D1 (de) 1998-12-23 2009-07-16 Glaxo Group Ltd Bestimmungsmethode fur liganden der nuklearen rezeptoren
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
JP4221129B2 (ja) * 1999-02-15 2009-02-12 富士フイルム株式会社 含窒素ヘテロ環化合物、有機発光素子材料、有機発光素子
US6071955A (en) * 1999-02-25 2000-06-06 The Regents Of The University Of California FXR, PPARA and LXRA activators to treat acne/acneiform conditions
US6316503B1 (en) 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
CA2368234A1 (en) 1999-03-26 2000-10-05 City Of Hope Method of affecting cholesterol catabolism using nuclear bile acid receptor
EP1177187B1 (en) 1999-04-28 2007-07-25 Sanofi-Aventis Deutschland GmbH Di-aryl acid derivatives as ppar receptor ligands
JP2003506097A (ja) 1999-06-18 2003-02-18 スィーヴィー セラピューティクス インコーポレイテッド Ａｔｐ結合カセット輸送体蛋白質ａｂｃ１を用いるコレステロール流出を増加させｈｄｌを上昇させるための組成物および方法
AU6074700A (en) 1999-07-08 2001-01-30 Tularik Inc. Compositions and methods for raising hdl cholesterol levels
ATE309536T1 (de) 1999-12-06 2005-11-15 Sangamo Biosciences Inc Methoden zur verwendung von randomisierten zinkfingerprotein-bibliotheken zur identifizierung von genfunktionen
US6602872B1 (en) 1999-12-13 2003-08-05 Merck & Co., Inc. Substituted pyridazines having cytokine inhibitory activity
WO2001060818A1 (en) 2000-02-14 2001-08-23 Tularik Inc. Lxr modulators
US6627647B1 (en) 2000-03-23 2003-09-30 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)imidazoles and their use as anti-inflammatory agents
US20020048572A1 (en) 2000-05-03 2002-04-25 Bei Shan Treatment of hypertriglyceridemia and other conditions using LXR modulators
AU2001258838A1 (en) 2000-05-29 2001-12-11 Kyorin Pharmaceutical Co. Ltd. Substituted phenylpropionic acid derivatives
US20050026811A1 (en) 2003-05-20 2005-02-03 Mjalli Adnan M. M. Rage antagonists as agents to reverse amyloidosis and diseases associated therewith
DE60227794D1 (de) * 2001-04-26 2008-09-04 Eisai R&D Man Co Ltd Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon
IL158693A0 (en) 2001-05-09 2004-05-12 Sumitomo Chem Takeda Agro Co Azole compounds, process for preparation of the same and use thereof
CN100344616C (zh) * 2001-06-12 2007-10-24 维尔斯达医疗公司 用于治疗代谢失调的化合物
HN2002000266A (es) 2001-09-24 2003-11-16 Bayer Corp Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad.
CA2458661A1 (en) * 2001-09-27 2003-04-03 Applied Research Systems Ars Holding N.V. Methods of increasing endogenous testosterone levels
US6924311B2 (en) 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
US6555563B1 (en) 2001-11-16 2003-04-29 Medinox, Inc. Heteroaryl substituted amidinyl and imidazolyl compounds and methods employing same for the treatment of inflammation
AU2003209388A1 (en) * 2002-01-29 2003-09-02 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
CN101597262A (zh) 2002-03-05 2009-12-09 特兰斯泰克制药公司 抑制配体与高级糖化终产物受体相互作用的单和双环吡咯衍生物
ATE422201T1 (de) * 2002-04-05 2009-02-15 Cadila Healthcare Ltd 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen
JP2005528384A (ja) 2002-04-08 2005-09-22 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション 増殖性細胞においてアポトーシスを誘導するための化合物および方法
EP1494667A1 (en) 2002-04-12 2005-01-12 Pfizer Japan Inc. Imidazole compounds as anti-inflammatory and analgesic agents
WO2004011446A1 (en) * 2002-07-26 2004-02-05 Bayer Pharmaceuticals Corporation Indane, dihydrobenzofuran, and tetrahydronaphthalene carboxylic acid derivatives and their use as antidiabetics
JP2005539000A (ja) * 2002-07-31 2005-12-22 スミスクライン・ビーチャム・コーポレイション Ａｌｋ５阻害剤としての２−フェニルピリジン−４−イル誘導体
TWI324596B (en) * 2002-08-26 2010-05-11 Nat Health Research Institutes Imidazolamino compounds
EP1398029A1 (en) 2002-09-10 2004-03-17 LION Bioscience AG NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives
WO2004028634A1 (en) * 2002-09-25 2004-04-08 The Board Of Trustees Of The University Of Illinois Method and composition for treating alzheimer's disease and dementias of vascular origin
JP2004137270A (ja) 2002-09-26 2004-05-13 Nippon Nohyaku Co Ltd 新規除草剤、その使用方法、新規置換チエノピリミジン誘導体及びその中間体並びにそれらの製造方法
JP4631259B2 (ja) 2002-10-03 2011-02-16 コニカミノルタホールディングス株式会社 有機エレクトロルミネッセンス素子及び表示装置
WO2004033432A1 (ja) * 2002-10-09 2004-04-22 Ssp Co., Ltd. 抗真菌活性を有する新規ピラゾール化合物
WO2004037248A2 (en) * 2002-10-24 2004-05-06 Carex Sa Modulation of peroxisome proliferator activated receptors activity
EP1578716A1 (en) 2002-12-20 2005-09-28 Novo Nordisk A/S Dicarboxylic acid derivatives as ppar-agonists
JP2006514043A (ja) * 2002-12-20 2006-04-27 ファルマシア・コーポレーション マイトジェン活性化タンパク質キナーゼ−活性化タンパク質キナーゼ−２を阻害する化合物
AU2003292218A1 (en) * 2002-12-23 2004-07-14 Sanofi-Aventis Deutschland Gmbh PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
US7396850B2 (en) 2003-01-06 2008-07-08 Eli Lilly And Company Pyrazole derivative as PPAR modulator
AU2004210127B2 (en) 2003-01-27 2009-10-01 Merck Sharp & Dohme Corp. Substituted pyrazoles, compositions containing such compounds and methods of use
CN1747936A (zh) 2003-02-12 2006-03-15 特兰斯泰克制药公司 作为治疗试剂的取代吡咯衍生物
JP4590825B2 (ja) * 2003-02-21 2010-12-01 コニカミノルタホールディングス株式会社 白色発光有機エレクトロルミネッセンス素子
EP1599447A1 (en) 2003-02-28 2005-11-30 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
WO2004080972A1 (en) * 2003-03-12 2004-09-23 Vertex Pharmaceuticals Incorporated Pirazole modulators of atp-binding cassette transporters
EP1613614A2 (en) 2003-04-03 2006-01-11 Merck & Co., Inc. Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5
DE10315569A1 (de) * 2003-04-05 2004-10-14 Merck Patent Gmbh Substituierte Pyrazolverbindungen
DE10315573A1 (de) 2003-04-05 2004-10-14 Merck Patent Gmbh Substituierte Pyrazole
DE10315571A1 (de) 2003-04-05 2004-10-14 Merck Patent Gmbh Pyrazolverbindungen
JP2006523719A (ja) * 2003-04-18 2006-10-19 メモリー・ファーマシューティカルズ・コーポレイション ホスホジエステラーゼ４抑制剤としてのピラゾール誘導体
PT1638943E (pt) 2003-05-27 2008-11-14 Conseils De Rech S Et D Aplica Novos derivados de imidazoles, sua preparação e sua utilização como medicamento
US20090018150A1 (en) * 2003-07-24 2009-01-15 Asterand Uk Limited 5-Ht2b Receptor Antagonists
JP2006528661A (ja) * 2003-07-25 2006-12-21 ファイザー・インク アミノピラゾール化合物およびｃｈｋ１阻害剤としての使用
JP4745971B2 (ja) 2003-10-03 2011-08-10 ザ オハイオ ステート ユニバーシティー リサーチ ファウンデーション ＰＤＫ−１／Ａｋｔシグナル伝達インヒビター
US7517900B2 (en) 2003-10-10 2009-04-14 Bristol-Myers Squibb Company Pyrazole derivatives as cannabinoid receptor modulators
JP2007508382A (ja) 2003-10-14 2007-04-05 イーライ リリー アンド カンパニー Ｐｐａｒモジュレータとしてのフェノキシエーテル誘導体
US20070060629A1 (en) 2003-10-17 2007-03-15 Yasuhiro Imanishi Large conductance calcium-activated k channel opener
US20070060596A1 (en) * 2003-10-24 2007-03-15 Giblin Gerard M P Heterocyclyl compounds
US8969372B2 (en) 2003-11-14 2015-03-03 Aptose Boisciences Inc. Aryl imidazoles and their use as anti-cancer agents
TW200526588A (en) 2003-11-17 2005-08-16 Smithkline Beecham Corp Chemical compounds
ES2299906T3 (es) 2003-11-25 2008-06-01 Eli Lilly And Company Moduladores de receptores activados por proliferadores de peroxisomas.
WO2005066137A1 (en) * 2003-12-19 2005-07-21 Neurogen Corporation 2,5-diaryl-1h-imidazole-4-carboxamides as neurokinin-3 receptor modulators for the treatment of central nervous system and peripheral diseases
CN1946391A (zh) 2004-04-20 2007-04-11 辉瑞产品公司 包含α－2－δ配体的组合
ITMI20041032A1 (it) * 2004-05-24 2004-08-24 Neuroscienze S C A R L Compositi farmaceutici
EP1785418A4 (en) 2004-08-06 2009-11-11 Daiichi Seiyaku Co PYRAZOLE DERIVATIVE
JP2006104191A (ja) 2004-09-07 2006-04-20 Sankyo Co Ltd 置換ビフェニル誘導体
WO2006028029A1 (ja) 2004-09-07 2006-03-16 Sankyo Company, Limited 置換ビフェニル誘導体
WO2006044528A1 (en) 2004-10-15 2006-04-27 Memory Pharmaceuticals Corporation Pyrazole derivatives as phosphodiesterase 4 inhibitors
EP2368881A1 (en) 2005-01-10 2011-09-28 University of Connecticut Heteropyrazole analogs acting on cannabinoid receptors
US20110144128A1 (en) * 2005-01-10 2011-06-16 Exelixis, Inc. Heterocyclic Carboxamide Compounds as Steroid Nuclear Receptors Ligands
CA2609394A1 (en) 2005-05-23 2006-11-30 Masaki Takagi Pyrazole compound and therapeutic agent for diabetes comprising the same
CA2613522A1 (en) 2005-06-27 2007-01-04 Exelixis, Inc. Imidazole based lxr modulators
US20080090834A1 (en) 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
CN101679297B (zh) 2006-12-08 2012-01-11 埃克塞利希斯股份有限公司 Lxr和fxr调节剂

Also Published As

Publication number Publication date
KR20080039381A (ko) 2008-05-07
US20100075964A1 (en) 2010-03-25
WO2007002559A8 (en) 2008-01-31
CA2613517A1 (en) 2007-01-04
TWI388323B (zh) 2013-03-11
TW200745045A (en) 2007-12-16
AU2006261841B2 (en) 2012-06-07
AR054521A1 (es) 2007-06-27
US20100331295A1 (en) 2010-12-30
ES2525217T3 (es) 2014-12-19
WO2007002563A1 (en) 2007-01-04
JP5244589B2 (ja) 2013-07-24
AU2006261845A1 (en) 2007-01-04
AU2006261841A1 (en) 2007-01-04
AU2006261841B8 (en) 2012-12-06
AR054522A1 (es) 2007-06-27
MY152162A (en) 2014-08-15
SG162804A1 (en) 2010-07-29
US20140038964A1 (en) 2014-02-06
PE20070187A1 (es) 2007-03-09
WO2007002559A1 (en) 2007-01-04
NZ564916A (en) 2011-03-31
US8569352B2 (en) 2013-10-29
EP1910307A1 (en) 2008-04-16
JP2008543971A (ja) 2008-12-04
BRPI0612287A2 (pt) 2011-03-15
JP2008543970A (ja) 2008-12-04
NO20080391L (no) 2008-03-19
JP5237799B2 (ja) 2013-07-17
PE20070105A1 (es) 2007-02-06
IL188239A0 (en) 2008-04-13
TW200738641A (en) 2007-10-16
EP1910308A1 (en) 2008-04-16
BRPI0612287A8 (pt) 2019-01-22
KR20080028964A (ko) 2008-04-02
EP1910308B1 (en) 2014-09-03
US9000022B2 (en) 2015-04-07
AU2006261845C1 (en) 2013-05-16
KR101363278B1 (ko) 2014-02-21
CA2613522A1 (en) 2007-01-04
US8703805B2 (en) 2014-04-22
AU2006261845B2 (en) 2012-09-13

Similar Documents

Publication Publication Date Title
MX2008000141A (es) Moduladores de lxr basados en imidazol.
SG162803A1 (en) Imidazole based lxr modulators
MX2009005462A (es) Analogos de 7,8-saturados-4,5-epoxi-morfinano.
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
UA94833C2 (en) Substituted bicyclolactams
MXPA05012680A (es) Indoles novedosos de 3-azufre sustituidos.
MY143367A (en) Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases
NO20081554L (no) Isoindollmidforbindelser og sammensetninger omfattende samme, og anvendelse derav
TN2011000585A1 (en) Lxr modulators
TW200728307A (en) Novel spirochromanone derivatives
MY151003A (en) Stable pharmaceutical composition comprising a pyrimidine-sulfamide
TW200612958A (en) Substituted imidazole derivatives
PT2421879E (pt) Novos 7-deazapurina nucleósidos para utilizações terapêuticas
TW200612936A (en) Indole derivatives
UA95257C2 (ru) 1-азабициклоалкилпроизводные для лечения психических расстройств
EP1861357A4 (en) NEW COMPOUNDS, ISOMERS THEREOF, OR PHARMACEUTICALLY SALTS SUCH AS VANILLOIDREZEPTORANTAGONIST, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ATE467632T1 (de) Pyrroloä2,3-büpyridinderivate als modulatoren des h3-rezeptors
HK1154777A1 (en) Lipoprotein lipase-activating compositions comprising benzene derivatives
EA200701687A1 (ru) Гидрохлорид аморфного лерканидипина
DE602004009200D1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
PL1845780T3 (pl) Zastosowanie pochodnych metylofenidatu
TW200738625A (en) 3-Amino-1-arylpropyl indoles and aza-substituted indoles
EA200801139A1 (ru) Композиция для аэрозольной ингаляции
ATE465151T1 (de) 4-aryloxy-chinolin-derivate als 5-ht6-modulatoren

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: EXELIXIS PATENT COMPANY LLC

FG Grant or registration